A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma

A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in... Ann Surg Oncol (2017) 24:2777–2784 DOI 10.1245/s10434-017-5921-4 OR IG INA L A R TIC L E – PA NC REATIC TU MO RS A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma 1 1 1 1 Keiichi Okano, MD, PhD, FACS , Hironobu Suto, MD , Minoru Oshima, MD, PhD , Eri Maeda, MD , 1 1 2 Naoki Yamamoto, MD, PhD , Keitaro Kakinoki, MD, PhD , Hideki Kamada, MD, PhD , Tsutomu Masaki, MD, 2 3 3 1 PhD , Shigeo Takahashi, MD , Toru Shibata, MD, PhD , and Yasuyuki Suzuki, MD, PhD Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Miki-cho, Kagawa, Japan; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki-cho, Kagawa, Japan; Department of Radiation Oncology, Faculty of Medicine, Kagawa University, Miki-cho, Kagawa, Japan ABSTRACT for Adverse Events (CTCAE) version 4.0] were anorexia Background. The ideal neoadjuvant treatment protocol (7%), nausea (5%), neutropenia (4%), and leukopenia for patients with pancreatic cancer (PDAC) remains (4%). No patient experienced grade 4 toxicity. Pathologi- unclear. We evaluated the efficacy and safety of neoadju- cally negative margins (R0) were achieved in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Surgical Oncology Springer Journals

A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma

Loading next page...
 
/lp/springer_journal/a-prospective-phase-ii-trial-of-neoadjuvant-s-1-with-concurrent-ZJafssfW0Z
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Society of Surgical Oncology
Subject
Medicine & Public Health; Surgical Oncology; Oncology; Surgery
ISSN
1068-9265
eISSN
1534-4681
D.O.I.
10.1245/s10434-017-5921-4
Publisher site
See Article on Publisher Site

Abstract

Ann Surg Oncol (2017) 24:2777–2784 DOI 10.1245/s10434-017-5921-4 OR IG INA L A R TIC L E – PA NC REATIC TU MO RS A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma 1 1 1 1 Keiichi Okano, MD, PhD, FACS , Hironobu Suto, MD , Minoru Oshima, MD, PhD , Eri Maeda, MD , 1 1 2 Naoki Yamamoto, MD, PhD , Keitaro Kakinoki, MD, PhD , Hideki Kamada, MD, PhD , Tsutomu Masaki, MD, 2 3 3 1 PhD , Shigeo Takahashi, MD , Toru Shibata, MD, PhD , and Yasuyuki Suzuki, MD, PhD Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Miki-cho, Kagawa, Japan; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki-cho, Kagawa, Japan; Department of Radiation Oncology, Faculty of Medicine, Kagawa University, Miki-cho, Kagawa, Japan ABSTRACT for Adverse Events (CTCAE) version 4.0] were anorexia Background. The ideal neoadjuvant treatment protocol (7%), nausea (5%), neutropenia (4%), and leukopenia for patients with pancreatic cancer (PDAC) remains (4%). No patient experienced grade 4 toxicity. Pathologi- unclear. We evaluated the efficacy and safety of neoadju- cally negative margins (R0) were achieved in

Journal

Annals of Surgical OncologySpringer Journals

Published: Jun 12, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off